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1.  INTRODUCTION
C
ervical cancer (CC) is the second leading cause
of cancer death in women globally and the first
in women in many developing countries[1,2]. In
sub Saharan Africa cervical cancer is the most common
cancer in women and there are over 200 million women
aged 15 years or older who are at potential risk of
cervical cancer.3 Nearly 71,000 cervical cancer cases
are diagnosed and approximately 62,000 deaths are
caused by cervical cancer each year in sub-Saharan
Africa.3 Experts believe that essentially all cases of
cervical cancer are caused by infection with oncogenic
types of human papillomavirus (HPV) [4-6].
HPV is a very common infection that is readily
transmitted during sexual contact. Therefore, most men
and women become infected with HPV soon after they
become sexually active. In most countries in the world,
70% to 80% of men and women will be exposed to
HPV infection at some point in their lives [7]. Condoms
are only partially effective in preventing HPV infections
[8,9].  A recent meta-analysis suggests that the overall
prevalence of HPV is higher in sub-Saharan Africa than
in other regions of the world with Eastern Africa having
the highest adjusted HPV prevalence (31.6%) [10].   The
prevalence and incidence of HPV infection also vary
between countries in the region due to different sexual
behaviours and societal norms. Even when women only
become sexually active at the time of marriage and have
only one lifetime partner, they are likely to acquire the
infection from their husbands if these men had sexual
experience before marriage.
There are more than 100 types of HPV infection
that infect many parts of the body, and a subset of these
cause genital infections [11]. Some genital HPV types
(referred to as oncogenic types of HPV) cause cancers
of the cervix [12], vulva [13,14], vagina [13], penis [15,
16] and anus [17].   Irrespective of global geographic
region, the most common HPV types found in
association with anogenital cancers are types 16 and
18.[7]. Cancer of the cervix is by far the most common
genital cancer and HPV is the necessary cause. Studies
have identified HPV in almost 100% of invasive cervical
cancer cases, 89% of high-grade squamous
intraepithelial (HSIL) lesions and 73% of low-grade
squamous intraepithelial (LSIL) lesions[18].  The most
potent cervical cancer causing HPV types are HPV 16
and 18, which together cause approximately 70% of
invasive cervical cancer cases[19] and are the
predominant HPV types identified in HSIL and LSIL
lesions [18]
Other genital HPV types are less likely to cause cancer
but can cause other HPV-related diseases [20, 21].    For
example, HPV types 6 and 11 cause approximately 90%
of genital wart cases.[22].   Decreasing the incidence of
HPV-related cancers, in particular cervical cancer
morbidity and mortality, by means such as vaccination
should therefore lead to a reduction in the human and
financial burden of such diseases.
Most cervical HPV infections resolve
spontaneously within 2 years [23], but in some women
invasive cervical cancer develops after one or more
decades of persistent infection with an oncogenic type
of HPV [24].  Intermediate stages in the development
of cervical cancer include abnormal Pap smears, low-
grade and high-grade cervical lesions as well as
carcinoma in situ. These predate the onset of invasive
cancer.[24].  Why some women do not clear the HPV
they have been exposed to and go on to develop cervical
lesions, is not well understood.
Secondary prevention methods such as visual
inspection with acetic acid (VIA), see-and-treat
management of cervical dysplasia, Pap testing and HPV
DNA testing will allow for detection of intermediate
lesions which are amenable to treatment and hence
prevention of most cases of cervical cancer in regularly
screened women [25].   Effective prevention using these
methods requires high levels of screening in the
population, an effective infrastructure to deliver the
screening, cultural acceptance of screening, the
availability of effective treatment, access of the
population to screening and treatment, and effective
follow-up. Although wealthy and middle income sub-
populations of women have access to this type of care
in sub-Saharan Africa, most women in these countries
have never received effective screening for cervical
cancer prevention.
Highly safe, immunogenic and effective vaccines
have recently been developed that can prevent infection
with HPV types 16 and 18 with or without 6 and 11.
These vaccines have now been licensed by the national
control authorities in more than 80 countries [26].
National immunisation programmes (NIPs) (with other
childhood vaccines) in sub-Saharan Africa are improving




Clinics in Mother and Child Health Vol 6, N° 1,  June 2009
more than 70% of infants[27].   However, most NIPs
do not have vaccines for administration to adolescents
and the older population. School and community-based
programmes are therefore thought by many experts to
be the correct setting for HPV vaccine administration.
School and community-based adolescent vaccination
programmes have been shown to have high completion
rates (>80%) [28,29], and are ideally suited for the
implementation of HPV vaccination schedules. Ideally,
both HPV immunisation and cervical cancer screening
programmes should be in place to have maximal impact
in preventing cervical cancer.
The discovery, development and testing of the new HPV
vaccines is a major medical achievement. The vaccine
is a virus-like particle (VLP) made by recombinant DNA
technology similar to the hepatitis B vaccine: the gene
for the L1 coat protein of the virus is inserted into another
cell (yeast or insect cell) which is grown in great quantities
in fermentation or tissue culture [25, 30].   The L1 coat
protein of the virus is then purified and self-assembled
into hollow VLPs that are highly immunogenic but non-
infectious since they do not contain nucleic acid. The
vaccines, which contain aluminium salts or the AS04
adjuvant (in the GSK vaccine), are highly immunogenic
and induce an immune response in almost 100% of
recipients of all ages tested to date (9 to 55 years of
age) [31].  The immune response has been shown to
last more than 6.4 years [32-34], and anamnestic
responses to booster doses of vaccine have been
documented [35]. The duration of protection of the
vaccine is at least 6.4 years [34], but the full duration of
protection is not yet known.
The vaccines have been shown to be highly
effective in preventing HPV infection and resultant
disease states [32].  Two vaccines are currently available
– a bivalent and a quadrivalent – both of which contain
VLPs of types 16 and 18 to prevent cervical cancer. In
addition, one of the vaccines (quadrivalent) contains
VLPs of types 6 and 11 to prevent genital warts. In
HPV naive women, studies with both HPV vaccines
have been shown to have more than 95% efficacy in
preventing HPV infection and the development of lesions
caused by the HPV types present in the vaccines for up
to 6.4 years of follow-up[36].  It is important to
understand that the current HPV vaccines are not
therapeutic and will have no effect on the disease process
of currently infected women. However, the vaccines may
prevent infection with vaccine-targeted HPV types in
women infected with other types of anogenital HPV.
Cost-effectiveness studies in industrial countries
have shown the vaccine to be highly cost-effective when
used as a routine vaccine in pre-adolescent girls,
adolescent girls and young women [37].  Few studies
have been done in developing countries, but studies in
Brazil have shown the vaccine to be cost-effective with
a lower vaccine cost [38]. Studies show that
immunisation of males and females is less cost-effective
than immunisation of females alone when the measured
outcome is cervical cancer prevention. However, HPV
infection in males can result in other HPV-related
diseases (e.g. anal and penile cancer)[15] which are a
significant burden on the health care system [39].
Vaccination of males could therefore reduce transmission
of HPV to females, resulting in a lower incidence of
HPV and fewer cases of cervical cancer, and prevent
male HPV-related diseases. There is concern that a
female-only strategy will be less culturally acceptable in
many countries. Male vaccination could therefore be a
consideration in some countries.
Expert committees in many countries have issued
recommendations for the use of these vaccines [40, 41].
This document provides model recommendations that
should be modified for use in individual countries in sub-
Saharan Africa.
2. IMMUNISATION STRATEGIES
2.1  Primary immunisation strategy
Most countries that have issued official recommendations
from expert groups have recommended that the primary
immunisation strategy should be to immunise pre-
adolescent girls in the range of 9 to 13 years of age (see
Table 1)[42].  This is to ensure that the immunisation is
given before the onset of sexual activity, and because
this group is easier to reach with the existing immunisation
infrastructure. School-based programmes are most
effective if most girls are in school at the recommended
age of vaccination and if school health programmes are
operational [42, 43].   Community-based immunisation
is also used in some countries [44].  Some countries
have allowed immunisation of both males and females
(e.g. Austria) but so far none has implemented universal
vaccination of boys [41].  Moreover, the impact of
immunising males has not yet been demonstrated in
clinical studies (which are pending). Ideally, routine
immunisation of pre-adolescent females should be done
as part of the national immunisation programme and
funded by the health care system. This will ensure high
coverage and is the most important strategy that will
lead to control of cervical cancer at a population level.
2.2  Catch-up immunisation strategy
Most countries also recommend a catch-up immunisation
strategy to ensure that the benefits of immunisation are
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providers, and together they can decide if immunisation
is appropriate.
-  Male vaccination is not recommended at this time but
this issue may be reassessed when data are available
and high vaccination coverage in the female population
has been achieved.
3.2  Co-administration
- HPV vaccine can be administered at the same visit
when other age appropriate vaccines are provided. Each
vaccination should, however, be administered individually
during the visit.
3.3  Screening
- At present, cervical cancer screening recommendations
have not changed for females who receive the HPV
vaccine. All women should receive regular cervical
cancer screening as recommended.
- Screening for cervical pathology or for the presence
of HPV is not required prior to vaccination.
-  A woman with abnormal screening/Pap smear result
is still eligible for vaccination unless, of course, the
woman has cervical carcinoma.
3.4  Special situations
-  The HPV vaccine can be given to females who have
an equivocal or abnormal Pap test result, a positive HPV
DNA or Hybrid Capture II® high risk test, or genital
warts.
-  Vaccine recipients should be advised that the data
from clinical trials do not demonstrate that the vaccine
will have any therapeutic effect on existing Pap test
abnormalities, HPV infection or genital warts. Vaccination
of these females would provide protection against
infection with vaccine HPV types 16 and 18 + 6 and 11
if not already acquired.
-  Lactating women can receive the quadrivalent HPV
vaccination [49]. The bivalent HPV vaccine should be
administered during breast-feeding only when the
possible advantages outweigh any possible risks [50].
-  Females who are immunocompromised either from
disease or medication can receive the HPV vaccine.
However, the immune response to vaccination and
vaccine effectiveness might be less than in females who
are immunocompetent [51]
3.5  Contraindications to use of vaccine
-  The HPV vaccine is contraindicated for people with a
history of immediate hypersensitivity to any vaccine
component.
- Women are discouraged from becoming pregnant
during the immunisation schedule.
- The HPV vaccine is not recommended for use in
pregnancy [25]
a.If a female has not finished her three-dose vaccination
course and becomes pregnant, she should not receive
any other vaccine doses until after delivery, at which
point the remaining dose(s) can be administered.
b. The vaccine has not been associated causally with
adverse outcomes of pregnancy or adverse events to
the developing foetus. However, data on vaccination
during pregnancy are limited.
3.6 Precautions
- The HPV vaccine can be administered to females with
minor acute illnesses (e.g., diarrhoea or mild upper
respiratory tract infections, with or without fever).
Vaccination of people with moderate or severe acute




- Each dose of the HPV vaccine is 0.5 mL and is
administered intramuscularly.
-  HPV vaccine is administered in a three-dose schedule.
The quadrivalent is recommended in a 0, 2, and 6-month
schedule; the bivalent vaccine should be administered
in a 0, 1, and 6-month schedule.
4.2  Adverse events
-  Serious adverse events are exceedingly rare. The most
common adverse events are pain, redness and swelling
at the site of the injection which are commonly mild in
nature 
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